이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sandu Pharmaceuticals 관리

관리 기준 확인 2/4

Sandu Pharmaceuticals' CEO는 Umesh Sandu, Jun2018 에 임명되었습니다 의 임기는 6.08 년입니다. 총 연간 보상은 ₹ 8.93M, 94.6% 로 구성됩니다. 94.6% 급여 및 5.4% 보너스(회사 주식 및 옵션 포함). 는 ₹ 79.34M 가치에 해당하는 회사 주식의 14.37% 직접 소유합니다. 79.34M. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 6.1 년입니다.

주요 정보

Umesh Sandu

최고 경영자

₹8.9m

총 보상

CEO 급여 비율	94.6%
CEO 임기	6.1yrs
CEO 소유권	14.4%
경영진 평균 재임 기간	6.1yrs
이사회 평균 재임 기간	6.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Umesh Sandu 의 보수는 Sandu Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	₹15m
Dec 31 2023	n/a	n/a	₹11m
Sep 30 2023	n/a	n/a	₹14m
Jun 30 2023	n/a	n/a	₹15m
Mar 31 2023	₹9m	₹8m	₹15m
Dec 31 2022	n/a	n/a	₹15m
Sep 30 2022	n/a	n/a	₹15m
Jun 30 2022	n/a	n/a	₹16m
Mar 31 2022	₹7m	₹7m	₹16m
Dec 31 2021	n/a	n/a	₹17m
Sep 30 2021	n/a	n/a	₹15m
Jun 30 2021	n/a	n/a	₹15m
Mar 31 2021	₹4m	₹3m	₹11m
Dec 31 2020	n/a	n/a	₹7m
Sep 30 2020	n/a	n/a	₹6m
Jun 30 2020	n/a	n/a	₹4m
Mar 31 2020	₹4m	₹3m	₹7m
Dec 31 2019	n/a	n/a	₹7m
Sep 30 2019	n/a	n/a	₹6m
Jun 30 2019	n/a	n/a	₹7m
Mar 31 2019	₹4m	₹3m	₹7m
Dec 31 2018	n/a	n/a	₹9m
Sep 30 2018	n/a	n/a	₹14m
Jun 30 2018	n/a	n/a	₹14m
Mar 31 2018	₹3m	₹3m	₹6m

보상 대 시장: Umesh 의 총 보상 ($USD 106.97K )은 Indian 시장( $USD 38.49K ).

보상과 수익: Umesh 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Umesh Sandu (57 yo)

6.1yrs

테뉴어

₹8,927,520

보상

Mr. Umesh Bhaskar Sandu serves as the Managing Director and Executive Director of Sandu Pharmaceuticals Limited since June 2, 2018 and served as its Company Secretary.

리더십 팀

이름	위치	테뉴어	보상	소유권
Umesh Sandu	MD & Executive Director	6.1yrs	₹8.93m	14.37% ₹ 84.3m
Pratika Mhambray	Compliance Officer & Company Secretary	9.3yrs	₹773.00k	데이터 없음
Vijay Kajrekar	Chief Financial Officer	less than a year	데이터 없음	데이터 없음

6.1yrs

평균 재임 기간

경험이 풍부한 관리: 524703 의 관리팀은 노련하고 경험 (평균 재직 기간 6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Umesh Sandu	MD & Executive Director	6.1yrs	₹8.93m	14.37% ₹ 84.3m
Shashank Sandu	Non-Executive Director	13.1yrs	₹51.00k	14.17% ₹ 83.1m
Shubhada Sandu	Non-Executive Director	9.3yrs	₹30.00k	0.10% ₹ 606.9k
Ajit Kantak	Non-Executive Independent Director	less than a year	데이터 없음	데이터 없음
Balaram Vishwanathan	Non Executive Independent Chairman	less than a year	데이터 없음	데이터 없음

6.1yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: 524703 의 이사회는 경험(평균 재직 기간 6 년)으로 간주됩니다.

Sandu Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Full year 2024 earnings released: EPS: ₹1.51 (vs ₹1.61 in FY 2023)

Sandu Pharmaceuticals Limited to Report Q4, 2024 Results on May 30, 2024

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: ₹0.21 (vs ₹0.51 in 3Q 2023)

Sandu Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited Announces CFO Changes

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹0.57 (vs ₹0.64 in 2Q 2023)

Investor sentiment improves as stock rises 19%

Sandu Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 13, 2023

Investor sentiment improves as stock rises 23%

Upcoming dividend of ₹0.75 per share at 1.1% yield

Full year 2023 earnings released: EPS: ₹1.62 (vs ₹1.99 in FY 2022)

New minor risk - Financial data availability

Sandu Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Sandu Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 14, 2023

Third quarter 2023 earnings released: EPS: ₹0.51 (vs ₹0.57 in 3Q 2022)

Sandu Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: EPS: ₹0.64 (vs ₹0.57 in 2Q 2022)

Insufficient new directors

Sandu Pharmaceuticals Limited to Report Q2, 2022 Results on Nov 14, 2022

Sandu Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹0.75 per share

Sandu Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended 31 March 2022

Sandu Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: EPS: ₹1.99 (vs ₹1.54 in FY 2021)

Sandu Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Sandu Pharmaceuticals Limited Approves Appointment of K Vinay Kumar as Chairman

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.57 (vs ₹0.56 in 2Q 2021)

Insufficient new directors

Sandu Pharmaceuticals Limited Resumed Manufacturing Operation to the Extent of 100% at Pilerne Industrial Estate, Goa

Sandu Pharmaceuticals Limited Resumes Partial Manufacturing Operation

Sandu Pharmaceuticals Limited Resumes Partial Manufacturing Operation

Sandu Pharmaceuticals Limited Announces Closure of Goa Factory

Investor sentiment improved over the past week

Sandu Pharmaceuticals Limited announced that it expects to receive INR 13.319198 million in funding from Akshath Finvest & Properties Pvt. Ltd., Neelambar leasing and Finvest Private, Sanbro Marketting Services Private Limited

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹0.41 (vs ₹0.22 in 3Q 2020)

Sandu Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 13, 2021

New 90-day high: ₹40.30

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: ₹32.65

Market bids up stock over the past week

Second quarter 2021 earnings released: EPS ₹0.56

Sandu Pharmaceuticals Limited to Report Q2, 2021 Results on Nov 13, 2020

Market pulls back on stock over the past week

New 90-day high: ₹25.85

First quarter earnings released

Full year earnings released - EPS ₹1.02

Sandu Pharmaceuticals Limited to Report Q1, 2021 Results on Sep 14, 2020

Sandu Pharmaceuticals Limited announced that it expects to receive INR 9.595 million in funding from Akshath Finvest & Properties Pvt. Ltd., and other investors

New 90-day high - ₹22.75

Full year earnings released - EPS ₹1.02

Sandu Pharmaceuticals Limited to Report Q4, 2020 Results on Jul 31, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간